GlassScriptPhysician profile
Walter P Miller
NPI 1851430961
$12,702.19
in general payments reported to CMS, 2019-2025
36 companies · $1,259 in 2025
The $1,259 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,778 · 2020: $1,333 · 2021: $2,071 · 2022: $2,251 · 2023: $2,144 · 2024: $1,866 · 2025: $1,259.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,251 · Education: $18.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,250.60 |
| Education | $18.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $4,303.62 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $2,052.89 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Amgen INC. | $1,364.68 | 2019-2023 | Repatha, Otezla, Evenity |
| Janssen Pharmaceuticals, INC | $607.09 | 2019-2024 | Xarelto |
| Pfizer INC. | $605.89 | 2019-2025 | |
| Lilly USA, LLC | $516.73 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Abbvie INC. | $389.96 | 2021-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $374.34 | 2022-2023 | |
| Radius Health, INC. | $339.03 | 2019-2025 | Tymlos |
| Novo Nordisk INC | $310.30 | 2019-2023 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $307.31 | 2019-2025 | Jardiance |
| Corcept Therapeutics | $277.67 | 2023-2024 | Korlym |
| E.R. Squibb & Sons, L.L.C. | $149.52 | 2019-2023 | Eliquis |
| Kowa Pharmaceuticals America, INC. | $145.92 | 2019-2023 | Livalo |
| Teva Pharmaceuticals USA, INC. | $131.51 | 2021-2023 | Austedo Xr |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Walter Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.